Arca Biopharma | ABIO - Equity Capital And Reserves


Arca Biopharma reported $469M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Amgen USD 9.19B 532M Mar/2026
Arca Biopharma USD 469M 17.79M Dec/2025
Biogen USD 18.65B 394.9M Mar/2026
Brainstorm Cell Therapeutics USD -9.98M 2.29M Dec/2025
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Capricor Therapeutics USD 305.79M 221.92M Dec/2025
Cipla INR 329.19B 16.3B Sep/2025
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 102.73M 58.9M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Grifols EUR 6.21B 133.12M Dec/2025
Laboratory Of America USD 8.73B 108.8M Mar/2026
Myriad Genetics USD 368M 4.8M Dec/2025
Otsuka Holdings JPY 3.11T 74.63B Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
United Therapeutics USD 7.1B 506M Dec/2025